Approval

Approval  ·  Weekly Digest - 17 January to 23 January 2026
ENHERTU approved in China as the first and only HER2 directed ADC for the second-Line treatment of patients with HER2 positive metastatic gastric cancer

Weekly Digest – January 2026 Weekly Digest – January 2026 22 January 2026: ENHERTU approved in China as the first and only HER2 directed ADC for the second-Line treatment of patients with HER2 positive metastatic gastric cancer  ENHERTU (trastuzumab deruxtecan) has been approved in China for the second-line treatment of adults with […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 17 January to 23 January 2026
Daiichi Sankyo Korea and AstraZeneca Korea receive approval for Enhertu for patients with HER2 low- and ultra-low-expression metastatic breast cancer treated with endocrine therapy

Weekly Digest – January 2026 Weekly Digest – January 2026 21 January 2026: Daiichi Sankyo Korea and AstraZeneca Korea receive approval for Enhertu for patients with HER2 low- and ultra-low-expression metastatic breast cancer treated with endocrine therapy  Daiichi Sankyo Korea and AstraZeneca Korea announced that Enhertu (trastuzumab deruxtecan) has received approval from Korea’s Ministry of Food […]

by Sandhya Ramalingam

Continue Reading